Our mission is to enhance target discovery for Alzheimer’s disease.

The Accelerating Medicines Partnership® (AMP®) Program Alzheimer’s disease (AMP AD 2.0) is a precompetitive public-private partnership that will enable precision medicine research for Alzheimer’s disease through deep and longitudinal molecular analyses across diverse populations to provide insights that will accelerate the development of therapies for Alzheimer’s disease.

This multisector partnership, managed by the Foundation for the NIH, will focus on providing a data-driven approach for identification and validation of biomarkers that will lead to increased clinical trial success.

AMP AD 2.0 builds on the success of AMP AD 1.0 and joins a portfolio of AMP programs that use cutting-edge scientific approaches to bring new medicines and support to patients by enhancing validation of novel, clinically relevant therapeutic targets and biomarkers.

  • Identify and validate new targets and biomarkers associated with different molecular subtypes of the disease to enable drug developers to select the right populations of patients for targeted treatments in clinical trials.

  • Enable mapping of Alzheimer’s disease progression on a cellular and molecular level and increase the availability of longitudinal data, giving researchers a more detailed and dynamic understanding of the disease.

  • Increase access to de-identified data from racially and ethnically diverse cohorts by prioritizing the addition of information to its centralized knowledge portal from populations most at risk, including Black and Latinx.

  • Enhance data-sharing capabilities by making individual subject-level data, analytical outputs, and target nominations available to researchers worldwide for use in basic research and therapy development.

A Growing Crisis

Alzheimer’s disease is a type of dementia that affects the brain, particularly areas related to memory, thinking, and behavior. It is a progressive condition, which means that symptoms worsen over time, and is projected to affect approximately 14 million people by the year 2060. Alzheimer’s disease is caused by the buildup of abnormal protein clumps and tangles in the brain, which damage and eventually kill brain cells. In the early stages of Alzheimer’s, a person may experience forgetfulness and difficulty with planning or problem-solving. This leads to a progressive loss of cognitive functions, and symptoms worsen and interfere with daily life and activities.

Need for New Therapies

Despite substantial investment in Alzheimer’s disease research, the treatment options available today only temporarily improve symptoms without stopping the underlying cognitive decline and death of brain cells. Given the extremely high failure rate for investigative Alzheimer’s treatments – nearly 100 percent – this field needs innovations to enable an understanding of the complex biology and heterogeneity of the disease process.


Private Sector Partners
Public Sector Partners

Deepening our understanding of Alzheimer’s disease at the molecular level and across diverse populations is an enormous undertaking—but critical to achieving the therapeutic breakthroughs we need. The AMP AD collaboration is leading the way in this effort and in ensuring the data, methods, and results are open and accessible.

-Niranjan Bose, Ph.D., Managing Director of Health & Life Sciences at Gates Ventures
nord logo

At Eisai, we believe collaboration is crucial in the fight against Alzheimer’s disease and we are proud to partner with leading organizations from the public, nonprofit and private sectors as part of Accelerating Medicines Partnership 2.0 for Alzheimer’s disease.

-Ivan Cheung, Chairman, Eisai Inc. and Global President, Neurology Business Group, Eisai Co., Ltd.
nord logo

Data Portals

AMP AD Knowledge Portal

Discover and download Alzheimer’s disease data, analyses, and tools from AMP AD.

Learn More
AMP AD Agora Platform

Agora is an open-source platform, created to provide curated AMP AD verified systems biology analyses showing which genes are associated with Alzheimer’s disease.

Learn More


Donate to the FNIH today to support medical research that saves lives

Partner With Us

Work with the FNIH to accelerate medical breakthroughs for patients